Mallinckrodt Public Limited Company Loss Form
Company: Mallinckrodt Public Limited Company
Ticker: (NYSE) MNK
Deadline
Passed
Lead Plaintiff Deadline: September 24, 2019
Never Miss Another Deadline
Choose your preferred way to stay informed of new case launches and settlement deadlines.
Get Updates by Email
Subscribe for email notifications.
Allegations
(i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.